Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
March 05, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
February 20, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
December 20, 2023 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished